Eric Huchot

Reunion Island
Island, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).

First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).

Journal: Clinical lung cancer
Published: November 17, 2024

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).

Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).

Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 20, 2024

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).

Journal: Targeted oncology
Published: October 21, 2023

Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).

Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).

Journal: Therapeutic advances in medical oncology
Published: May 30, 2023

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Journal: Targeted oncology
Published: May 10, 2023

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).

Journal: Clinical lung cancer
Published: June 25, 2022

Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.

Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 14, 2022

Molecular profile of non-small cell lung cancer in reunion Island.

Molecular profile of non-small cell lung cancer in reunion Island.

Journal: Respiratory medicine and research
Published: October 15, 2021

Survival and epidemiological characteristics of women with lung cancer in Reunion

Survival and epidemiological characteristics of women with lung cancer in Reunion

Journal: Revue des maladies respiratoires
Published: January 12, 2021

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019.

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019.

Journal: Cancers
Published: November 06, 2020

Coxiella burnetii: A Hidden Pathogen in Interstitial Lung Disease?

Coxiella burnetii: A Hidden Pathogen in Interstitial Lung Disease?

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 16, 2017

Self medication with Annona muricata L. (corossol) as an anti-cancer agent in Reunion

Self medication with Annona muricata L. (corossol) as an anti-cancer agent in Reunion

Journal: Revue des maladies respiratoires
Published: March 23, 2017
Showing 1-12 of 13

Last Updated: 09/26/2026